N4 Pharma a deeper understanding of the capabilities of Nuvec (Interview)

N4 Pharma plc (LON:N4P) CEO Nigel Theobald joins DirectorsTalk Interviews to discuss interim results for the six months ended 30 June 2021. Nigel talks us through the highlights, talks about the increased understanding of the capabilities of Nuvec, progress on the two MTA´s, patents from the European, Australian, and Japanese patent offices and what can investors expect from N4 Pharma in the next 6 months.

N4 Pharma, are a specialist pharmaceutical company developing a novel silica nanoparticle delivery system for vaccines and therapeutics for licensing to pharmaceutical and biotech partners.

Find more news, interviews, share price & company profile here for:

    Share this interview

    Twitter
    LinkedIn
    Facebook
    Email
    WhatsApp